Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for …
PURPOSE Calcineurin inhibitors (CNI) are standard components of graft-versus-host
disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data …
disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data …
Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia
About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not
achieve molecular complete remission or who subsequently relapse are not cured by …
achieve molecular complete remission or who subsequently relapse are not cured by …
The development of post-transplant cyclophosphamide: Half a century of translational team science
PV O'Donnell, RJ Jones - Blood reviews, 2023 - Elsevier
Close HLA matching of donors and recipients has been the dogma for successful allogeneic
blood or marrow transplantation (alloBMT), to limit the complications of graft-versus-host …
blood or marrow transplantation (alloBMT), to limit the complications of graft-versus-host …
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide
Allogeneic blood or marrow transplantation (BMT) physicians seek to optimize all possible
variables to improve outcomes. Selectable factors include conditioning, graft-versus-host …
variables to improve outcomes. Selectable factors include conditioning, graft-versus-host …
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute …
J Sanz, JE Galimard, M Labopin, B Afanasyev… - Journal of Hematology & …, 2021 - Springer
Background There is no information on the impact of donor type in allogeneic hematopoietic
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …
[HTML][HTML] Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
Haploidentical donors offer a potentially readily available donor, especially for non-White
patients, for hematopoietic cell transplantation (HCT). In this North American collaboration …
patients, for hematopoietic cell transplantation (HCT). In this North American collaboration …
Post-transplantation cyclophosphamide is associated with increased bacterial infections
C Ustun, M Chen, S Kim, JJ Auletta… - Bone marrow …, 2024 - nature.com
Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host
disease after hematopoietic cell transplantation (HCT); however, it might be associated with …
disease after hematopoietic cell transplantation (HCT); however, it might be associated with …
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions
I Abou Dalle, N Moukalled, J El Cheikh, M Mohty… - Leukemia, 2024 - nature.com
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …
How to manage Philadelphia-positive acute lymphoblastic leukemia in resource-constrained settings
Simple Summary Remarkable strides have been performed in the treatment of adults
diagnosed with Philadelphia-positive lymphoblastic leukemia (Ph+ ALL) through the …
diagnosed with Philadelphia-positive lymphoblastic leukemia (Ph+ ALL) through the …
Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for …
We describe outcomes after post-transplantation cyclophosphamide and nonmyeloablative
conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using …
conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using …